These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26622939)

  • 1. TNF-R1, an immune checkpoint in melanoma?
    Bertrand F; Colacios C; Ségui B
    Genes Cancer; 2015 Sep; 6(9-10):369-70. PubMed ID: 26622939
    [No Abstract]   [Full Text] [Related]  

  • 2. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
    Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
    Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8
    Kobayashi T; Oishi K; Okamura A; Maeda S; Komuro A; Hamaguchi Y; Fujimoto M; Takehara K; Matsushita T
    J Invest Dermatol; 2019 Jul; 139(7):1535-1544.e1. PubMed ID: 30836062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer.
    Grimm M; Kim M; Rosenwald A; von Raden BH; Tsaur I; Meier E; Heemann U; Germer CT; Gasser M; Waaga-Gasser AM
    Eur J Cancer; 2010 Aug; 46(12):2314-23. PubMed ID: 20580220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma.
    Kharkevitch DD; Seito D; Balch GC; Maeda T; Balch CM; Itoh K
    Int J Cancer; 1994 Aug; 58(3):317-23. PubMed ID: 7914181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
    Edwards J; Tasker A; Pires da Silva I; Quek C; Batten M; Ferguson A; Allen R; Allanson B; Saw RPM; Thompson JF; Menzies AM; Palendira U; Wilmott JS; Long GV; Scolyer RA
    Clin Cancer Res; 2019 Jun; 25(11):3247-3258. PubMed ID: 30777877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
    Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
    Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
    Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
    Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
    Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
    Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
    Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
    Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
    Zhu J; Powis de Tenbossche CG; Cané S; Colau D; van Baren N; Lurquin C; Schmitt-Verhulst AM; Liljeström P; Uyttenhove C; Van den Eynde BJ
    Nat Commun; 2017 Nov; 8(1):1404. PubMed ID: 29123081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
    Maccalli C; Mortarini R; Parmiani G; Anichini A
    Int J Cancer; 1994 Apr; 57(1):56-62. PubMed ID: 7908659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.